

Transthyretin Amyloid Cardiomyopathy - Pipeline Insight, 2021

<https://marketpublishers.com/r/T529C1517355EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: T529C1517355EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Transthyretin Amyloid Cardiomyopathy (ATTR-CM) – Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Understanding

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Overview

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a disease caused by the destabilization of a transport protein called transthyretin which leads to the abnormal deposition of amyloid protein in the heart. The disease is characterized by the depositions of amyloid protein fibrils in the left ventricle walls, which is the main pumping chamber of the heart. ATTR-CM has two subtypes- wild type and hereditary type. The wild type ATTR-CM happens without mutation and is thought to occur due to aging and majorly affects men above the age of 60. The Hereditary ATTR-CM is said to occur due to the mutation in the transthyretin gene and may be observed in individuals

in the 50-60 age group.

“Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) pipeline landscape is provided which includes the disease overview and Transthyretin Amyloid Cardiomyopathy (ATTR-CM) treatment guidelines. The assessment part of the report embraces, in depth Transthyretin Amyloid Cardiomyopathy (ATTR-CM) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Transthyretin Amyloid Cardiomyopathy (ATTR-CM) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Transthyretin Amyloid Cardiomyopathy (ATTR-CM) R&D. The therapies under development are focused on novel approaches to treat/improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Emerging Drugs Chapters

This segment of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Emerging Drugs

Acoramidis (AG 10): Eidos Therapeutics

Eidos therapeutics' drug candidate AG 10 is in the phase III stage of drug development currently. The molecule was designed to stabilize TTR by copying the T119M- TTR variant's structure.

NI006: NeuralImmune Therapeutics

NI006, a NeuralImmune Therapeutics' drug candidate is a human antibody that specifically targets only the disease-associated conformation of the amyloid protein. The drug molecule is capable of targeting both the ATTR linked with hereditary ATTR-CM as well as the wild type. Currently, it is in the Phase I of the drug development.

Further product details are provided in the report.....

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Therapeutic Assessment

This segment of the report provides insights about the different Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

There are approx. 3+ key companies which are developing the therapies for Transthyretin Amyloid Cardiomyopathy (ATTR-CM). The companies which have their Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drug candidates in the mid to advanced stage, i.e. phase III include, NeuralImmune Therapeutics and others.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late-stage products(Phase III)

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Natural metabolites

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Transthyretin Amyloid Cardiomyopathy (ATTR-CM) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Transthyretin

Amyloid Cardiomyopathy (ATTR-CM) drugs.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Report Insights

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drugs?

How many Transthyretin Amyloid Cardiomyopathy (ATTR-CM) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Eidos Therapeutics

NeuralImmune Therapeutics

Key Products

Acoramidis

NI006

Contents

Introduction

Executive Summary

Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) companies' collaborations, Licensing, Acquisition -Deal Value Trends

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Acoramidis: Eidos Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase I)

Comparative Analysis

NI006: NeuralImmune Therapeutics

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Pre-clinical and Discovery Stage Products
 Comparative Analysis
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
 Comparative Analysis
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Key Companies
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Key Products
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)- Unmet Needs
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)- Market Drivers and Barriers
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)- Future Perspectives and
Conclusion
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Analyst Views
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Transthyretin Amyloid Cardiomyopathy - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/T529C1517355EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T529C1517355EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970